Few cancer patients engage with genomic testing: What to know

Advertisement

Most patients with advanced or metastatic cancer do not undergo genomic testing, according to a study published April 7 in JAMA Network Open. 

Researchers from Salt Lake City-based Huntsman Cancer Institute, Dallas-based University of Texas Southwestern Medical Center, Kansas City-based University of Kansas Cancer Center and Cleveland-based University Hospitals Seidman Cancer Center, analyzed patient data from 280 U.S. cancer clinics to assess uptake of next-generation sequencing.

Here are three things to know from the study:

  1. Between Jan. 1, 2018, and Dec. 30, 2022, 63,294 patients with advanced or metastatic cancer underwent next-generation sequencing.

    Next-generation sequencing uptake increased among patients diagnosed in 2022 compared with 2018 across all cancer types.

  2. “Although the 1-year cumulative incidence of next-generation sequencing improved over time across all cancer types, the majority of patients with cancer did not undergo next-generation sequencing,” the study authors wrote.

  3. Patients with low socioeconomic status, Black or Hispanic patients, and patients with Medicaid or Medicare coverage had a significantly longer time between diagnosis and next-generation sequencing.

Read the full study here.

Advertisement

Next Up in Oncology

Advertisement